Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apollo: Neoadjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma
NCT05761132Phase 2Unknown
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2023
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in vulvar squamous cell carcinoma (VSCC), sponsored by Leiden University Medical Center. Status: unknown.
02
Drugs
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NCT05761132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761132.